Website
News25/Ratings7
News · 26 weeks45-22%
2025-10-262026-04-19
Mix1990d
- Other6(32%)
- SEC Filings6(32%)
- Insider6(32%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form DEFR14A filed by Senseonics Holdings Inc.DEFR14A - Senseonics Holdings, Inc. (0001616543) (Filer)
- SECSEC Form DEFA14A filed by Senseonics Holdings Inc.DEFA14A - Senseonics Holdings, Inc. (0001616543) (Filer)
- SECSEC Form DEF 14A filed by Senseonics Holdings Inc.DEF 14A - Senseonics Holdings, Inc. (0001616543) (Filer)
- INSIDERSEC Form 4 filed by Roeder Douglas A4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERSEC Form 4 filed by Prince Douglas S4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERSEC Form 4 filed by Steven Edelman4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERSEC Form 4 filed by Fiorentino Edward4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- SECSEC Form PRE 14A filed by Senseonics Holdings Inc.PRE 14A - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRMedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValueIssued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac
- INSIDERDirector Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERPresident and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- PRFirst Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of WearNew data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered comparable adherence and outcomes between the first and second six-month period, indicating high accuracy and performance from a single sensor across an entire year GERMANTOWN, Md., March 14, 2026 (GLOBE NEWSWIRE) -- Senseonics, a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces new data from a real-world evidence study which demonstrates the s
- SECSenseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- SECSEC Form 10-K filed by Senseonics Holdings Inc.10-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- SECSenseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRSenseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsGenerated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase
- PRSequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S. Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world's only one-year CGM. This powerful combination is a significant leap forward for the diabetes community, offering a t
- PRSenseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose MonitorGERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system. Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year. The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and is now approved for commercialization in
- PRSenseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceGERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah. To request a meeting with Senseonics, investors should contact their BTIG representatives. About SenseonicsSenseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monito
- SECSenseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRSenseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business UpdatePreliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite
- PRSenseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) SystemGERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have launched the integration of their products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM. The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics' Eversens
- INSIDERDirector Fiorentino Edward was granted 2,398 shares, increasing direct ownership by 3% to 71,363 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Roeder Douglas A was granted 2,504 shares, increasing direct ownership by 3% to 102,231 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Prince Douglas S was granted 1,379 shares, increasing direct ownership by 2% to 56,743 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)